by Barry101 | Aug 19, 2016 | Press Release
PHILADELPHIA, Aug. 19, 2016 — Hemispherx Biopharma (NYSE MKT:HEB) announced that it has formed a scientific advisory board (SAB). The purpose of the SAB is to leverage its member’s scientific and pharmaceutical expertise and advice to advance the...
by Barry101 | Aug 17, 2016 | Press Release
PHILADELPHIA, Aug. 17, 2016 — Hemispherx Biopharma (NYSE MKT:HEB) (the “Company), announced today that it will effect a 1-for-12 reverse stock split of its common stock.At the annual meeting of the Company’s stockholders held earlier today, the...
by Barry101 | Aug 15, 2016 | Press Release
The company continues to focus on commercial success by seeking co-development partners and working closely with the research and regulatory communities to bring disease fighting technologies to the world.Conference Call Scheduled for Friday, August 19, 2016 at 11:00...
by Barry101 | Aug 15, 2016 | Press Release
PHILADELPHIA, Aug. 15, 2016 — Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) has posted the transcript of The Wall Street Transcript interview with Thomas Equels and William Mitchell, PhD, MD. The...
by Barry101 | Jul 27, 2016 | Press Release
PHILADELPHIA, July 27, 2016 — Hemispherx Biopharma (NYSE MKT:HEB) (“Hemispherx” or the “Company”) announced today that it has reached an agreement with Avrio Biopharmaceuticals (“Avrio”), Irvine California, to serve as an...
by Barry101 | Jul 25, 2016 | Press Release
PHILADELPHIA, July 25, 2016 — Hemispherx Biopharma (NYSE MKT:HEB) announced today that the first order of rintatolimod (Ampligen®) for the Early Access Program (EAP) in Europe has been shipped with receipt confirmed on July 22. On May 23, 2016, the Company...
